<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="174661">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822094</url>
  </required_header>
  <id_info>
    <org_study_id>CLTR0308-205</org_study_id>
    <nct_id>NCT00822094</nct_id>
  </id_info>
  <brief_title>Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR &gt; 1 Month Duration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celator Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Celator Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates if CPX-351 will be a) more effective than the standard intensive
      salvage AML treatment and b) more tolerable than the standard intensive salvage treatment
      regimens.

      The study compares the investigational product CPX-351 vs the standard intensive salvage
      treatment for first relapse AML patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-label, parallel-arm, fixed-dose, standard therapy
      controlled Phase IIB trial. Study enrollment duration is expected to be approximately 12-18
      months. On entry, patients are randomized to receive either CPX-351 or intensive first
      salvage treatment.

      Patients are stratified to balance the likelihood of obtaining a CR and the duration of CR
      between the two arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Overall Survival at 1 year</measure>
    <time_frame>Up to 1 year from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>Following 1st induction, following 2nd induction if applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Up to 1 year from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission Duration</measure>
    <time_frame>Following achievement of CR and up to 1 year from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Aplasia</measure>
    <time_frame>Up to 1 year from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Stem Cell Transplant</measure>
    <time_frame>Up to 1 year from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early induction mortality at day 30 and at day 60 from start of 1st induction</measure>
    <time_frame>day 30 and day 60 from 1st induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late mortality</measure>
    <time_frame>following Day 90 from 1st induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac toxicity by monitoring of left ventricular ejection fraction changes</measure>
    <time_frame>Up to 1 year from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPX-351</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigators choice of an Intensive Salvage Therapy for remission induction (non-palliative) purposes (for example: &quot;HiDAC&quot; (high dose ara-d, anthracycline), &quot;MEC&quot; (mitoxantrone, etoposide, cytarabine), &quot;7 + 3&quot; (cytarabine, daunorubucin))</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>100u/m2 will be administered on study days 1, 3 and 5 as a 90 minute infusion</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Salvage Therapy</intervention_name>
    <description>Investigators choice of an Intensive Salvage Therapy as used for remission induction</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and voluntarily sign an informed consent form

          -  Age ≥18 and ≤65 years at the time of relapse

          -  Pathological confirmation of relapsed AML after initial CR of &gt;1 month duration

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0- 2

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Laboratory values fulfilling the following:

               -  Serum creatinine &lt; 2.0 mg/dL

               -  Serum total bilirubin &lt; 2.0 mg/dL

               -  Serum alanine aminotransferase or aspartate aminotransferase &lt;3xULN Note: If
                  elevated liver enzymes are related to disease; contact medical monitor to
                  discuss.

          -  Cardiac ejection fraction &gt; 50% by echocardiography or MUGA scan

          -  All men and women must agree to practice effective contraception during the study
             period and for 3 months afterward if not otherwise documented to be infertile.

        Exclusion Criteria:

          -  Patients with active second malignancies are excluded. Patients with second
             malignancies in remission may be eligible if there is no clinical evidence of active
             disease, documented by imaging, with tumor marker studies, etc., at screening.
             Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy,
             are eligible. In all cases, the second malignancy and its non-chemotherapy treatment
             must not interfere with the investigators ability to assess the safety or efficacy of
             the study treatment

          -  Patients with acute promyelocytic leukemia [t(15;17)]

          -  Total lifetime anthracycline exposure exceeding the equivalent of 368 mg/m2 of
             daunorubicin (or equivalent) prior to start of study therapy

          -  Any serious medical condition, laboratory abnormality or psychiatric illness that
             would prevent obtaining informed consent

          -  Administration of any antineoplastic therapy within 4 weeks of therapy; intended to
             treat first relapse. In the event of rapidly proliferative disease use of hydroxyurea
             is permitted until 24 hours before the start of study treatment

          -  Clinical evidence of active CNS leukemia

          -  Patients with history of and/or current evidence of myocardial impairment (e.g.
             cardiomyopathy, ischemic heart disease, significant valvular dysfunction,
             hypertensive heart disease, and congestive heart failure) resulting in New York Heart
             Association Class III or IV staging

          -  Active and uncontrolled infection. Patients with a bacterial infection receiving
             treatment with antibiotics may be entered into the study if they are afebrile and
             hemodynamically stable for &gt;72 hrs.

          -  Current evidence of invasive fungal infection (blood or tissue culture); active
             hepatitis C infection or known HIV infection

          -  Hypersensitivity to cytarabine, daunorubicin or liposomal products

          -  History of Wilson's disease or other copper-related disorder

          -  Patients with a history of severe toxicity related to receiving conventional dose
             cytarabine in first line treatment (approximately 100mg/m2/d for &lt;7 days) are
             excluded. Patients who experienced unacceptable toxicities while receiving high dose
             cytarabine (approximately 3000mg/m2 for 6 doses) will not be treated again with the
             same regimen, but could be randomized to treatment with conventional dose cytarabine
             regimens where the risk of major toxicity is less.

          -  Woman who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kolitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center Section of Hematology/Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine General Medical Center Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Waterville</city>
        <state>Maine</state>
        <zip>04901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center, Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore LIJ Center for Advanced Medicine Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center/Mecklenburg Medical Group</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital of Cincinatti</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology at Lehigh Valley</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTMB Comprehensive Cancer Center</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center at The University of TX Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital/ British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 049</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Sang CHU de Lille, Hopital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Sang Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie CHU Toulouse-Hôpital Purpan</name>
      <address>
        <city>Toulouse Cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie et Médecine Interne CHU de Nancy-Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im. M. Kopernika</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologii</name>
      <address>
        <city>Opole</city>
        <zip>45-372</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademia Medyczna we Wroclawlu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.celatorpharma.com</url>
    <description>Company Website</description>
  </link>
  <link>
    <url>http://www.lls.org/hm_lls</url>
    <description>The Leukemia and Lymphoma Society</description>
  </link>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 20, 2013</lastchanged_date>
  <firstreceived_date>January 12, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>February 20, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Myeloid</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Adult</keyword>
  <keyword>First</keyword>
  <keyword>Relapse</keyword>
  <keyword>AML</keyword>
  <keyword>Acute Myelogenous leukemia</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Myeloid, Acute</keyword>
  <keyword>Acute myelocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
